reviewHuman Vaccines & ImmunotherapeuticsMar 19, 2019BRONZE OA

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Shanghai Jiao Tong University · Shanghai Ninth People's Hospital · +1 more institution

PubMed
Indexed incrossrefdoajpubmed

Abstract

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation. Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, and the development of anti-PD-1/PD-L1 antibodies has recently become a hot topic in cancer immunotherapy. Here, we review the structure of PD-1 and PD-L1, the function of the PD-1/PD-L1 signaling pathway, the application of PD-1 or PD-L1 monoclonal antibodies and future directions for…

Citation impact

618
total citations
FWCI
20.07
Percentile
100%
References
89
Citations per year

Authors

4

Topics & keywords

Keywords
  • PD-L1
  • Immunotherapy
  • Cancer immunotherapy
  • Immune checkpoint
  • Tumor microenvironment
  • Cancer research
  • Blockade
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding